-
Mashup Score: 10The value of anticancer drugs — a regulatory view - Nature Reviews Clinical Oncology - 2 year(s) ago
In oncology, a definition of drug value that patients, payers, regulators and clinicians agree upon on does not exist. The authors of this Perspective discuss different approaches to measuring value, such as assessments of benefit–risk balance and cost-effectiveness, individual attitudes to risk, and use of scales developed to measure value objectively. They also explain how regulators can help…
Source: Nature Reviews Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer - Nature Reviews Clinical Oncology - 2 year(s) ago
Targeted therapies have improved the outcomes of many patients with cancer, although many more lack targetable alterations or do not derive clinical benefit for other reasons. Radiotherapy can also provide benefit to many patients, although radioresistance often limits the effectiveness of this intervention. Here, the authors describe the potential for radiotherapy to promote non-oncogene…
Source: Nature Reviews Clinical OncologyCategories: Latest Headlines, Oncologists2Tweet-
Estrategia: Terapia A: funciona en X% de tumores que expresan "a" Terapia B: hace que (X+Y)% de tumores expresen "a" y así funcione la Terapia A. Terapia A = Terapia dirigida Terapia B = Radioterapia https://t.co/y4ualCW2Wn
-
-
Mashup Score: 8
Nature Reviews Clinical Oncology –
Aumolertinib is effective in NSCLC Source: Nature Reviews Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a research highlight now live, we discuss the results of the APOLLO trial of aumolertinib in EGFR T790M-mutated NSCLC https://t.co/3koZx2YhaQ https://t.co/lCHzfPlDeb
-
-
Mashup Score: 15Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer - Nature Reviews Clinical Oncology - 2 year(s) ago
Targeted therapies have improved the outcomes of many patients with cancer, although many more lack targetable alterations or do not derive clinical benefit for other reasons. Radiotherapy can also provide benefit to many patients, although radioresistance often limits the effectiveness of this intervention. Here, the authors describe the potential for radiotherapy to promote non-oncogene…
Source: Nature Reviews Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a Review now published online, @GiuliaPetroni10 @deadoc80 and cols discuss how radiotherapy can elicit actionable signalling pathways in patients with cancer @WCMEnglanderIPM @WCM_MeyerCancer #WCMRadonc https://t.co/p7Zb61uQAE https://t.co/OQiw4WsLoz
-
-
Mashup Score: 4COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials - Nature Reviews Clinical Oncology - 2 year(s) ago
Patients with cancer have a high risk of morbidity and mortality from COVID-19. The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease. Herein, the COVID19 and Cancer Clinical Trials Working Group calls for prioritization of patients with cancer, importantly including those participating in oncology clinical trials, for COVID-19 vaccination. The authors also…
Source: Nature Reviews Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials https://t.co/o8YclGT62w
-
-
Mashup Score: 12Predicting cancer outcomes with radiomics and artificial intelligence in radiology - Nature Reviews Clinical Oncology - 2 year(s) ago
Prognostication of outcome across multiple cancers and prediction of response to various treatment modalities are among the next generation of challenges that artificial intelligence (AI) tools can solve using radiology images. The authors of this Perspective describe the evolution of AI-based approaches in oncology imaging and address the path to their adoption as decision-support tools in the…
Source: Nature Reviews Clinical OncologyCategories: Latest Headlines, Oncologists1Tweet-
#ArtificialIntelligence in radiology is a promising tool to identify new predictive & prognostic biomarkers for use in clinical decision-making. Original datasets are expanding in oncology for #immunotherapy #targetedtherapies & chemotherapy. https://t.co/l39hhVlC6j https://t.co/OGLQcUwnHF
-
-
Mashup Score: 2The FDA’s latest move to expand eligibility for oncology trials — a double-edged sword? - Nature Reviews Clinical Oncology - 2 year(s) ago
Recent FDA draft guidance for sponsors of oncology clinical trials encourages enrolment of patients with incurable cancer and no potential for prolonged and/or near-normal survival, regardless of whether they have received existing treatment options. This guidance constitutes a substantial departure from current standards, with potentially profound implications for trial participants as well as…
Source: Nature Reviews Clinical OncologyCategories: Latest Headlines, Oncologists2Tweet-
Are these NRCO authors suggesting that people with advanced cancer should only have access to investigational agents--even in #clinicaltrials--*after* they've exhausted every FDA-approved agent including old chemo? @NatRevClinOncol https://t.co/aUy8webs8l? #cancer #advocacy https://t.co/HogyIK4UWA
-
-
Mashup Score: 7
Nature Reviews Clinical Oncology –
Early ICI uptake on PET predicts response Source: Nature Reviews Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Early ICI uptake on PET predicts response in pts with melanoma or NSCLC: https://t.co/f1svrVjhpx #LCSM #melsm #ImmunoOnc #oncorad https://t.co/enRlPUWxaM
-
-
Mashup Score: 0EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment - Nature Reviews Clinical Oncology - 3 year(s) ago
EGFR exon 19 deletions and exon 21 mutations, and HER2 amplification and/or overexpression, are predictive of response to matched molecularly targeted therapies that have greatly improved patient outcomes. However, insertion mutations in exon 20 of either EGFR or HER2 generally do not confer sensitivity to these therapies. In this Review, the authors discuss the prevalence of EGFR and HER2 exon…
Source: Nature Reviews Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment | Nature Reviews Clinical Oncology https://t.co/hU89fFaOt4
-
-
Mashup Score: 2Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond - Nature Reviews Clinical Oncology - 3 year(s) ago
Daratumumab is an anti-CD38 monoclonal antibody that has transformed the landscape of treatment both for transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma. Addressing important ongoing questions, such as when to de-escalate therapy, will be an important step forward in delivering patient-centred care for those with newly diagnosed multiple myeloma.
Source: Nature Reviews Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a Comment now published online, @ManniMD1 and @HiraSMian discuss the role of daratumumab in newly diagnosed #myeloma with examples from pivotal trials https://t.co/03dr0AQvT9 https://t.co/Kb4hY2SEHl
-
In a new Perspective now live, Francesco Pignatti et al. discuss the value of oncology drugs from the point of view of regulators https://t.co/oCJsUXHdoW https://t.co/xJdsEZygWZ